COUNTERPOINT: Should Triple Inhaled Therapy Be Considered in All Patients With Group E COPD? No
Chest
.
2024 Jul;166(1):17-20.
doi: 10.1016/j.chest.2024.03.031.
Author
Samy Suissa
1
Affiliation
1
Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital, and the Department of Epidemiology and Biostatistics and of Medicine, McGill University, Montreal, QC, Canada. Electronic address:
[email protected]
.
PMID:
38986634
DOI:
10.1016/j.chest.2024.03.031
No abstract available
Publication types
Editorial
MeSH terms
Administration, Inhalation
Bronchodilator Agents* / administration & dosage
Bronchodilator Agents* / therapeutic use
Drug Therapy, Combination
Humans
Pulmonary Disease, Chronic Obstructive* / drug therapy
Substances
Bronchodilator Agents